China Regenerative Medicine International Ltd
08158
Company Profile
Business description
China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.
Contact
132 Nathan Road
Suite 2310-2318, Miramar Tower
Tsim Sha Tsui
Kowloon
HKGT: +852 39189000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.30 | 45.40 | -0.50% |
| CAC 40 | 8,211.50 | 16.29 | 0.20% |
| DAX 40 | 24,868.69 | 329.35 | 1.34% |
| Dow JONES (US) | 48,977.18 | 594.79 | 1.23% |
| FTSE 100 | 10,004.57 | 53.43 | 0.54% |
| HKSE | 26,513.76 | 166.52 | 0.63% |
| NASDAQ | 23,395.82 | 160.19 | 0.69% |
| Nikkei 225 | 52,236.17 | 403.37 | 0.78% |
| NZX 50 Index | 13,648.86 | 61.63 | 0.45% |
| S&P 500 | 6,902.05 | 43.58 | 0.64% |
| S&P/ASX 200 | 8,718.30 | 53.00 | -0.60% |
| SSE Composite Index | 4,032.31 | 8.89 | 0.22% |